Seres Therapeutics, Inc.
Seres Therapeutics is a clinical stage biotechnology company dedicated to transforming the lives of patients worldwide with revolutionary live biotherapeutics. They focus on creating new treatments for medically vulnerable populations to prevent bacterial bloodstream and antimicrobial resistant infections, as well as to treat GI-related immune diseases. Their pioneering science and robust development pipeline aim to modulate the human microbiome to address serious diseases.
Industries
Nr. of Employees
medium (51-250)
Seres Therapeutics, Inc.
101 Cambridge Park Drive, Cambridge MA 02140
Patents
Synergistic bacterial compositions and methods of production and use thereof
US-12083151-B2
View DetailsSynergistic bacterial compositions and methods of production and use thereof
US-11918612-B2
View DetailsSynergistic bacterial compositions and methods of production and use thereof
US-11458173-B2
View DetailsSynergistic bacterial compositions and methods of production and use thereof
US-11458174-B2
View Details
Synergistic bacterial compositions and methods of production and use thereof
US-12083151-B2
View DetailsSynergistic bacterial compositions and methods of production and use thereof
US-11918612-B2
View DetailsSynergistic bacterial compositions and methods of production and use thereof
US-11458173-B2
View DetailsSynergistic bacterial compositions and methods of production and use thereof
US-11458174-B2
View DetailsProducts
FDA‑approved oral live biotherapeutic for recurrent C. difficile (asset sold Sept 2024)
An oral, highly purified live bacterial therapeutic approved to prevent recurrence of C. difficile infection in adults; the product asset was sold to a third party in September 2024.
FDA‑approved oral live biotherapeutic for recurrent C. difficile (asset sold Sept 2024)
An oral, highly purified live bacterial therapeutic approved to prevent recurrence of C. difficile infection in adults; the product asset was sold to a third party in September 2024.
Services
Clinical operations, trial execution, data management and biostatistics support for live biotherapeutic clinical programs.
Integrated in-house process development, GMP manufacturing, quality control and quality assurance for oral bacterial consortium products.
Regulatory affairs expertise including preparing biologics license applications and securing FDA designations.
Organized donor recruitment and stool collection program to supply samples for strain isolation and research.
Clinical operations, trial execution, data management and biostatistics support for live biotherapeutic clinical programs.
Integrated in-house process development, GMP manufacturing, quality control and quality assurance for oral bacterial consortium products.
Regulatory affairs expertise including preparing biologics license applications and securing FDA designations.
Organized donor recruitment and stool collection program to supply samples for strain isolation and research.
Expertise Areas
- Microbiome therapeutics development
- Clinical trial management for biologics and live biotherapeutics
- Biomanufacturing and CMC for live bacterial products
- Biomarker discovery and translational research
Key Technologies
- Microbial genomics and metagenomics
- Metabolomics
- Computational modeling and bioinformatics
- Organoid and human tissue assays
News & Updates
VOWST™ received FDA approval in April 2023 to prevent the recurrence of C. difficile infection in adults.
VOWST™ received FDA approval in April 2023 to prevent the recurrence of C. difficile infection in adults.